United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

United Therapeutics Co. (NASDAQ:UTHR) has been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $382.08.

Several research analysts recently issued reports on the company. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. TD Cowen upped their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $370.58 on Tuesday. The stock has a market capitalization of $16.55 billion, a P/E ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics has a 1-year low of $211.61 and a 1-year high of $417.82. The business has a fifty day moving average price of $362.00 and a 200 day moving average price of $359.42.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 121,864 shares of company stock worth $44,516,965 over the last quarter. 11.90% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $25,000. Brooklyn Investment Group acquired a new stake in shares of United Therapeutics in the third quarter worth approximately $33,000. Dunhill Financial LLC boosted its stake in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 50 shares during the last quarter. State of Wyoming acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $62,000. Finally, Millstone Evans Group LLC acquired a new stake in shares of United Therapeutics in the fourth quarter worth approximately $67,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.